Why CAR-T policymaking is broken, and why we need to fix it

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The initial reports of the near-miraculous benefits of CAR-T in pediatric acute lymphoblastic leukemia generated tremendous excitement—there was a Lazarus-like quality to these stories.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Michael Kolodziej
Vice president and chief innovation officer, ADVI Health
Louis Jacques
Chief clinical officer and senior vice president, ADVI Health; Former director of the Coverage and Analysis Group, Centers for Medicare and Medicaid Services
Marc Samuels
Chief executive officer, ADVI Health
Table of Contents

YOU MAY BE INTERESTED IN

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 
Michael Kolodziej
Vice president and chief innovation officer, ADVI Health
Louis Jacques
Chief clinical officer and senior vice president, ADVI Health; Former director of the Coverage and Analysis Group, Centers for Medicare and Medicaid Services
Marc Samuels
Chief executive officer, ADVI Health

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login